双歧杆菌三联活菌散联合保肝治疗对乙型肝炎肝硬化患者肠道菌群及炎性因子水平的影响

Effects of live combined Bifidobacterium,Lactobacillus and Enterococcus powder,oral combined with liver protection therapy on intestinal flora and inflammatory factors levels in patients with hepatitis B cirrhosis

目的探讨双歧杆菌三联活菌散联合保肝治疗对乙型肝炎肝硬化患者肠道菌群及炎性因子水平的影响。方法选取2019年3月至2022年5月我院收治的124例乙型肝炎肝硬化患者作为研究对象,根据投掷硬币法将其分为参照组和研究组,每组62例。参照组给予常规保肝及对症治疗,研究组在参照组基础上给予双歧杆菌三联活菌散治疗。比较两组的治疗效果。结果治疗后,研究组的层粘连蛋白(LN)、透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)及Ⅳ型胶原(Ⅳ-C)水平低于参照组(P<0.05)。治疗后,研究组的白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)及白细胞介素-6(IL-6)水平低于参照组(P<0.05)。治疗后,研究组的D-乳酸(DLC)、内毒素(ET)及降钙素原(PCT)水平低于参照组(P<0.05)。治疗后,研究组的双歧杆菌、肠球菌、乳酸杆菌及拟杆菌数量多于参照组,酵母样真菌数量少于参照组(P<0.05)。结论双歧杆菌三联活菌散联合保肝治疗乙型肝炎肝硬化患者的效果显著,不仅能够有效调节肝纤维化指标、炎性因子以及肠道通透性指标水平,还能促进肠道菌群平衡。

Objective To investigate the effects of live combined Bifidobacterium,Lactobacillus and Enterococcus powder,oral combined with liver protection therapy on intestinal flora and inflammatory factors levels in patients with hepatitis B cirrhosis.Methods A total of 124 patients with hepatitis B cirrhosis admitted in our hospital from March 2019 to May 2022 were selected as the research objects.According to the coin toss method,the patients were divided into reference group and study group,with 62 cases in each group.The reference group was given routine liver protection and symptomatic therapy,and the study group was given live combined Bifidobacterium,Lactobacillus and Enterococcus powder,oral therapy on the basis of the reference group.The therapeutic effects of the two groups were compared.Results After treatment,the levels of laminin(LN),hyaluronic acid(HA),procollagen typeⅢ(PC-Ⅲ)and collagen typeⅣ(Ⅳ-C)in the study group were lower than those in the reference group(P<0.05).After treatment,the levels of interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)and interleukin-6(IL-6)in the study group were lower than those in the reference group(P<0.05).After treatment,the levels of D-lactic acid(DLC),endotoxin(ET)and procalcitonin(PCT)in the study group were lower than those in the reference group(P<0.05).After treatment,the numbers of Bifidobacterium,Enterococcus,Lactobacillus and Bacteroides in the study group were more than those in the reference group,and the number of yeast-like Fungi was less than that in the reference group(P<0.05).Conclusion The live combined Bifidobacterium,Lactobacillus and Enterococcus powder,oral combined with liver protection in the treatment of patients with hepatitis B cirrhosis has a significant effect,it can not only effectively regulate the liver fibrosis indexes,inflammatory factors and intestinal permeability indexes levels,but also promote the balance of intestinal flora.